We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$697M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
-6.51%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$202M
AUM Growth
-$68.1M
(-25%)
Cap. Flow
-$45.1M
Cap. Flow
% of AUM
-22.3%
Top 10 Holdings %
Top 10 Hldgs %
75.02%
Holding
62
New
16
Increased
10
Reduced
11
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$30.7M |
| 2 |
GE HealthCare
GEHC
|
+$14.1M |
| 3 |
Cigna
CI
|
+$10.1M |
| 4 |
ADC Therapeutics
ADCT
|
+$7.97M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
+$7.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
|
+$23.4M |
| 2 |
STAAR Surgical
STAA
|
+$7.63M |
| 3 |
Icon
ICLR
|
+$6.6M |
| 4 |
HSKA
Heska Corp
HSKA
|
+$5.61M |
| 5 |
Protagonist Therapeutics
PTGX
|
+$4.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.68% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Orchestra BioMed
OBIO
$254M
| – | – |
-250,000
| Closed | -$2.5M |
|
|
52
Protagonist Therapeutics
PTGX
$9.44B
| – | – |
-434,635
| Closed | -$4.74M |
|
53
Relmada Therapeutics
RLMD
$519M
| – | – |
-235,500
| Closed | -$822K |
|
|
54
PUT
Relmada Therapeutics
RLMD
$519M
| – | – |
-235,600
| Closed | -$822K |
|
|
55
STAAR Surgical
STAA
$1.21B
| – | – |
-157,129
| Closed | -$7.63M |
|
56
Tyra Biosciences
TYRA
$1.58B
| – | – |
-152,159
| Closed | -$1.16M |
|
57
X4 Pharmaceuticals
XFOR
$438M
| – | – |
-60,865
| Closed | -$1.81M |
|
|
CBAY
58
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-555,610
| Closed | -$3.48M |
|
|
RETA
59
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-67,000
| Closed | -$2.55M |
|
|
ISEE
60
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-86,400
| Closed | -$1.85M |
|
|
RXDX
61
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-574,200
| Closed | -$63.2M |
|
|
MSAC
62
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| – | – |
-2,323,000
| Closed | -$23.4M |
|
Similar funds
GUB
KLI
AAM
TCM
CA
SAM
ACM
MCM
Sio Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Sio Capital Management held 62 positions worth $202M, down 25% from $270M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Sio Capital Management withdrew a net $45.1M in Q1 2023, closing 18 positions and reducing 11 holdings. Its most notable exit was Medicus Sciences Acquisition Corp. Class A Ordinary Share, an estimated $23.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 60% a quarter earlier, followed by Financials.
Against the trend, Sio Capital Management opened a new position in Centene worth $27.4M.
- Sio Capital Management's largest Q1 2023 buy was Centene: 432,834 shares worth $27.4M.
- Sio Capital Management added most to Cigna in Q1 2023, an estimated $10.1M increase.
- Sio Capital Management's biggest Q1 2023 reduction was Heska Corp, cutting an estimated $5.61M.
- Sio Capital Management fully exited Medicus Sciences Acquisition Corp. Class A Ordinary Share in Q1 2023, selling an estimated $23.4M.
- Sio Capital Management's ten largest holdings make up 75% of its $202M portfolio in Q1 2023.
- Sio Capital Management opened 16 new positions and closed 18 in Q1 2023.
- Sio Capital Management's portfolio value fell 25% quarter-over-quarter to $202M.
Based on Sio Capital Management's 13F filing for Q1 2023, filed 12 May 2023.